ABSTRACT
Introduction: Adult-onset foveomacular vitelliform dystrophy is a prevalent form of macular degeneration and typically occurs between the fourth and sixth decades of life.
Areas covered: A pubmed and medline search was performed using the relevant key words. Several variants of the term ‘adult-onset vitelliform macular dystrophy’ were searched in relation to different terms: ‘diagnosis’, ‘managment’ and ‘treatment’.
Expert commentary: Multimodal diagnostic imaging methods such as autofluorescence, fluorescein angiography, indocyanine green angiography, structural spectral domain optical coherence tomography, and optical coherence tomography angiography have led to a better understanding of the pathophysiological features of macular diseases. Gene therapy is a promising future option for treating monogenic forms of adult-onset foveomacular vitelliform dystrophy.
Declaration of interest
F Bandello is a consultant for Alcon (Fort Worth,Texas,USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California,USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee,Belgium), Zeiss (Dublin, California, USA). G Querques is a consultant for Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California,USA), Heidelberg (Germany), Novartis (Basel, Switzerland), Bayer Shering-Pharma (Berlin, Germany), Zeiss (Dublin, California, USA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.